Journal Article
. 2020 Jun;12(6).
doi: 10.3390/cancers12061549.

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer

Lutfi H Alfarsi 1 Rokaya El Ansari 1 Brendah K Masisi 1 Ruth Parks 1 Omar J Mohammed 1 Ian O Ellis 1 Emad A Rakha 1 Andrew R Green 1 
Affiliations
  • PMID: 32545448
  •     35 References

Abstract

Endocrine therapy is the mainstay of adjuvant treatment for patients with luminal breast cancer. Despite ongoing advances in endocrine therapy to date, a proportion of patients ultimately develop endocrine resistance, resulting in failure of therapy and poor prognosis. Therefore, as part of the growing concept of personalised medicine, the need for identification of predictive markers of endocrine therapy response at an early stage, is recognised. The METABRIC series was used to identify differentially expressed genes (DEGs) in term of response to adjuvant endocrine therapy. Drebrin 1 (DBN1) was identified as a key DEG associated with response to hormone treatment. Next, large, well-characterised cohorts of primary luminal breast cancer with long-term follow-up were assessed at the mRNA and protein levels for the value of DBN1 as a prognostic marker in luminal breast cancer, as well as its potential for predicting the benefit of endocrine therapy. DBN1 positivity was associated with aggressive clinicopathological variables and poor patient outcomes. Importantly, high DBN1 expression predicted relapse patients who were subject to adjuvant endocrine treatment. Our results further demonstrate that DBN1 is an independent prognostic marker in luminal breast cancer. Its association with the response to endocrine therapy and outcome provides evidence for DBN1 as a potential biomarker in luminal breast cancer, particularly for the benefit of endocrine treatment. Further functional investigations into the mechanisms underlying sensitivity to endocrine therapy is required.

Keywords: DBN1; breast cancer; endocrine resistance; oestrogen receptor; predictive biomarker.

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
Małgorzata Szostakowska, Alicja Trębińska-Stryjewska, Ewa Anna Grzybowska, Anna Fabisiewicz.
Breast Cancer Res Treat, 2018 Nov 02; 173(3). PMID: 30382472    Free PMC article.
Review.
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs.
Yuxing Liao, Jing Wang, +2 authors, Bing Zhang.
Nucleic Acids Res, 2019 May 23; 47(W1). PMID: 31114916    Free PMC article.
Highly Cited.
Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Lutfi H Alfarsi, Rokaya El-Ansari, +5 authors, Andrew R Green.
Int J Mol Sci, 2020 Feb 26; 21(4). PMID: 32093034    Free PMC article.
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
M Stendahl, A Kronblad, +3 authors, G Landberg.
Br J Cancer, 2004 May 13; 90(10). PMID: 15138475    Free PMC article.
Drebrin, an actin-binding, cell-type characteristic protein: induction and localization in epithelial skin tumors and cultured keratinocytes.
Wiebke K Peitsch, Ilse Hofmann, +5 authors, Werner W Franke.
J Invest Dermatol, 2005 Sep 28; 125(4). PMID: 16185277
Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model.
Ranjana Mitra, Jinseon Lee, +19 authors, David A Potter.
Clin Cancer Res, 2011 Jan 19; 17(9). PMID: 21242119    Free PMC article.
F-actin-binding protein drebrin regulates CXCR4 recruitment to the immune synapse.
Manuel Pérez-Martínez, Mónica Gordón-Alonso, +12 authors, Francisco Sánchez-Madrid.
J Cell Sci, 2010 Mar 11; 123(Pt 7). PMID: 20215400
A novel role for drebrin in regulating progranulin bioactivity in bladder cancer.
Shi-Qiong Xu, Simone Buraschi, +8 authors, Andrea Morrione.
Oncotarget, 2015 Apr 04; 6(13). PMID: 25839164    Free PMC article.
CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis.
Yanan Sun, Xiaoyun Mao, +7 authors, Feng Jin.
Tumour Biol, 2014 May 09; 35(8). PMID: 24810923    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer.
Yasuhiro Saito, Lewyn Li, +6 authors, Senthil K Muthuswamy.
Nature, 2019 Apr 19; 569(7755). PMID: 30996345
Highly Cited.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer.
Pascal Jézéquel, Mario Campone, +4 authors, Loïc Campion.
Breast Cancer Res Treat, 2011 Apr 01; 131(3). PMID: 21452023
Highly Cited.
Control of cell shape and plasticity during development and disease by the actin-binding protein Drebrin.
Xin-peng Dun, John K Chilton.
Histol Histopathol, 2010 Feb 26; 25(4). PMID: 20183806
Review.
Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.
Lutfi Alfarsi, Simon Johnston, +2 authors, Andrew R Green.
Histopathology, 2018 Apr 01; 73(4). PMID: 29603357
Review.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.
Willi Sauerbrei, Sheila E Taube, +2 authors, Douglas G Altman.
J Natl Cancer Inst, 2018 Jun 07; 110(8). PMID: 29873743    Free PMC article.
Highly Cited. Review.
The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
Rokaya El Ansari, Madeleine L Craze, +5 authors, Andrew R Green.
Breast Cancer Res, 2018 Mar 24; 20(1). PMID: 29566741    Free PMC article.
Highly Cited.
The drebrin/EB3 pathway drives invasive activity in prostate cancer.
A E Dart, D C Worth, +6 authors, P R Gordon-Weeks.
Oncogene, 2017 Mar 21; 36(29). PMID: 28319065    Free PMC article.
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Balazs Györffy, Andras Lanczky, +4 authors, Zoltan Szallasi.
Breast Cancer Res Treat, 2009 Dec 19; 123(3). PMID: 20020197
Highly Cited.
The role of drebrin in glioma migration and invasion.
Yuzo Terakawa, Sameer Agnihotri, +5 authors, James T Rutka.
Exp Cell Res, 2012 Dec 04; 319(4). PMID: 23201135
Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Jie Yuan, Manran Liu, +8 authors, Guanglun Yang.
Breast Cancer Res, 2015 May 21; 17. PMID: 25990368    Free PMC article.
Mechanisms of endocrine resistance in breast cancer.
C Kent Osborne, Rachel Schiff.
Annu Rev Med, 2010 Oct 05; 62. PMID: 20887199    Free PMC article.
Highly Cited. Review.
MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.
Ayesha N Shajahan-Haq, Katherine L Cook, +6 authors, Robert Clarke.
Mol Cancer, 2014 Oct 24; 13. PMID: 25339305    Free PMC article.
Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis.
Lorena Hernandez, Marco A O Magalhaes, +2 authors, Jeffrey E Segall.
Breast Cancer Res, 2011 Dec 14; 13(6). PMID: 22152016    Free PMC article.
ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap.
Tauno Metsalu, Jaak Vilo.
Nucleic Acids Res, 2015 May 15; 43(W1). PMID: 25969447    Free PMC article.
Highly Cited.
iTRAQ analysis of colorectal cancer cell lines suggests Drebrin (DBN1) is overexpressed during liver metastasis.
Qifeng Lin, Hwee Tong Tan, +3 authors, Maxey C M Chung.
Proteomics, 2014 Mar 13; 14(11). PMID: 24610677
Silencing of CXCR4 blocks breast cancer metastasis.
Zhongxing Liang, Younghyoun Yoon, +3 authors, Hyunsuk Shim.
Cancer Res, 2005 Feb 12; 65(3). PMID: 15705897    Free PMC article.
Highly Cited.
The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.
Osvaldo Pontiggia, Rocio Sampayo, +5 authors, Marina Simian.
Breast Cancer Res Treat, 2011 Sep 22; 133(2). PMID: 21935603    Free PMC article.
Drebrin: A new oncofetal biomarker associated with prognosis of lung adenocarcinoma.
Shinji Iyama, Masao Ono, +6 authors, Masayuki Noguchi.
Lung Cancer, 2016 Dec 19; 102. PMID: 27987592
A weighted average difference method for detecting differentially expressed genes from microarray data.
Koji Kadota, Yuji Nakai, Kentaro Shimizu.
Algorithms Mol Biol, 2008 Jun 27; 3. PMID: 18578891    Free PMC article.
Histochemical approaches to steroid receptor analyses.
K S McCarty, K S McCarty.
Semin Diagn Pathol, 1984 Nov 01; 1(4). PMID: 6400637
Review.
CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Lutfi H Alfarsi, Rokaya El Ansari, +5 authors, Andrew R Green.
Breast Cancer Res Treat, 2019 Sep 01; 178(3). PMID: 31471836
Drebrin particles: components in the ensemble of proteins regulating actin dynamics of lamellipodia and filopodia.
W K Peitsch, I Hofmann, +5 authors, W W Franke.
Eur J Cell Biol, 2001 Oct 26; 80(9). PMID: 11675932
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo.
Catherine C Park, Hui Zhang, +4 authors, Mina J Bissell.
Cancer Res, 2006 Feb 03; 66(3). PMID: 16452209    Free PMC article.
Highly Cited.